Analysts think ACLX stock price could increase by 64%
Jan 15, 2026, 12:25 PM
-1.88%
What does ACLX do
Arcellx, based in Redwood City, California, focuses on innovative immunotherapies for cancer, with its lead product, CART-ddBCMA, in pivotal Phase II trials for multiple myeloma. The company also develops two clinical-stage programs targeting BCMA and CD123 in various blood cancers.
19 analysts think ACLX stock price will increase by 63.59%. The current median analyst target is $114.24 compared to a current stock price of $69.83. The lowest analysts target is $88.88 and the highest analyst target is $140.70.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.